News

BioAlliance Pharma obtains european approval for Loramyc® tablet embossing and extension of its shelf life to 36 months

BioAlliance Pharma SA (Euronext Paris: BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced Europe-wide approval for embossing its Loramyc® mucoadhesive buccal tablet, developed for the treatment of oropharyngeal candidiasis. The embossing process has thus been approved under the Mutual Recognition Procedure; it was first required for the US market, where BioAlliance…read more →

Combined Extraordinary and Ordinary General Meeting on July 27th 2009

Procedures for obtaining preparatory documents BioAlliance Pharma’s shareholders are invited to attend the Combined Extraordinary and Ordinary General Meeting to be held at 10.00 am on July 27th 2009 at the company’s head office (49 Boulevard du Général Martial Valin, F-75015 Paris, France). The official notice of the Meeting will be published in the French Republic’s Bulletin des Annonces Légales…read more →

BioAlliance Pharma submits loramyc® NDA to us FDA

and announces a general shareholders’ meeting to amend its by-laws BioAlliance Pharma SA (Euronext Paris: BIO), a company dedicated to the treatment of cancer and AIDS patients and supportive care, today announced the submission of its New Drug Application (NDA) to the United States Food and Drug Administration (FDA), as planned, for the approval of Loramyc®, Mucoadhesive Buccal Tablets (MBT),…read more →

Upcoming BioAlliance Pharma’s presentations at international Conferences on infectious diseases and oncology

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to therapies and supportive care for cancer and AIDS patients, today announced its scientific communications at upcoming international conferences on infectious diseases and oncology: Loramyc®, indicated for fungal infections in immune-compromised patients with HIV or cancer The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting May 29 to June…read more →

Change on bioalliance pharma management board

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced Pierre Morgon’s departure. Management Board Member Pierre Morgon joined BioAlliance Pharma in 2008 primarily in order to supervise the company’s commercial operations in Europe. “As a consequence of our new organization in Europe with the search of…read more →

BioAlliance Pharma to resubmit Loramyc® NDA In the second quarter of 2009

BioAlliance Pharma SA (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections, on cancer and on AIDS, today announced that based on a recent ad hoc meeting held with the FDA, the NDA for Loramyc® will be resubmitted in the second quarter of 2009. If approved, Par Pharmaceutical/Strativa, BioAlliance Pharma’s partner for Loramyc commercialization in…read more →

Q1 2009 turnover

Sustained growth and a solid cash situation Significant portfolio developments BioAlliance Pharma SA (Euronext Paris – BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced a consolidated turnover of €2.6 million for Q1 2009. Revenues Loramyc® sales totaled €0.4 million, reflecting the product’s sustained commercial success. Almost 7000 patients were treated…read more →

BioAlliance Pharma presents results on its new oral Irinotecan nanoparticle formulation for the treatment of advanced colorectal cancer at the American Association for Cancer Research (AACR) 100th Annual Meeting in Denver, April 18 to 22, 2009

BioAlliance Pharma SA (Euronext Paris – BIO), a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has presented results on its oral Irinotecan nanoparticle formulation for the treatment of advanced colorectal cancer at the American Association for Cancer Research (AACR) 100th Annual Meeting, in Denver, April 18 to 22, 2009. Colorectal cancer is the…read more →

BioAlliance Pharma presents results on its new biotherapy plasmid AMEP™ for metastatic melanoma at the American Association for Cancer Research (AACR) 100th Annual Meeting in Denver, April 18 to 22, 2009

BioAlliance Pharma SA (Euronext Paris – BIO), a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has presented results on its new biotherapy, plasmid AMEP™, for metastatic melanoma treatment at the at the American Association for Cancer Research (AACR) 100th Annual Meeting, in Denver, April 18 to 22, 2009. Worldwide melanoma incidence is about…read more →

BioAlliance Pharma to complete NDA for Loramyc® with data on Debossed mucoadhesive tablet

BioAlliance Pharma SA (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced that the FDA did not accept the NDA for Loramyc® (miconazole) mucoadhesive buccal tablet (MBT) to be filed based on the lack of a tablet imprint code. Loramyc® was approved in Europe in 2007 and is currently…read more →

Publication of the 2008 Annual Report

BioAlliance Pharma SA (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced that its 2008 Annual Report, in its capacity as Reference Document, was registered with the French Market Authorities on Tuesday, April 7, 2009. It is available free of charge to the public upon request as per current…read more →

BioAlliance Pharma announces that it has initiated arbitration proceedings in the International Chamber of Commerce against SpePharm and SpeBio

BioAlliance Pharma SA (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, announces that it has filed a request for arbitration against SpePharm and SpeBio with the Arbitration Court of the International Chamber of Commerce in order to obtain reparation for the damage caused to it by non-compliance with contractual obligations…read more →

Combined Ordinary and Extraordinary General Meeting on April 29th 2009

Procedures for obtaining preparatory documents BioAlliance Pharma’s shareholders are invited to attend the Combined Ordinary and Extraordinary General Meeting to be held at 2.00 pm on April 29th 2009 at the company’s head office (49 Boulevard du Général Martial Valin, F-75015 Paris, France). The official notice of the Meeting will be published in the French Republic’s Bulletin des Annonces Légales…read more →

BioAlliance Pharma receives €6.4 million in funding

for the development of its innovative cancer therapeutics BioAlliance Pharma SA (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced the award of €6.4 million in funding from OSEO (the French state innovation agency). The company will devote the funds to the development of its novel therapeutic entities for…read more →

Full-year accounts for 2008

• Revenues: + 134% • Loramyc® is creating value • Commercial synergies in the near future • 2008 end-of-year cash reserves: €32 million BioAlliance Pharma SA (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today presented its consolidated financial results for the fiscal year ended December 31, 2008. 2008 was…read more →